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Abstract
Purpose To report the real-world incidence and risk fac-
tors of stent thrombosis in the aortoiliac and femor-
opopliteal arteries in case of bare nitinol stent (BNS) or
covered nitinol stent (CNS) placement from a single-centre
retrospective audit.
Materials and Methods Medical records of consecutive
patients treated with peripheral stent placement for clau-
dication or critical limb ischemia were audited for definite
stent thrombosis defined as imaging confirmed stent
thrombosis that presented as acute limb-threatening ische-
mia. Cases were stratified between aortoiliac and femor-
opopliteal anatomy. Cox regression analysis was employed
to adjust for baseline clinical and procedural confounders
and identify predictors of stent thrombosis and major limb
loss.
Results 256 patients (n = 277 limbs) were analysed over a
5-year period (2009–2014) including 117 aortoiliac stents
(34 CNS; 12.8 ± 5.0 cm and 83 BNS; 7.8 ± 4.0 cm) and
160 femoropopliteal ones (60 CNS; 21.1 ± 11.0 cm and
100 BNS; 17.5 ± 11.9 cm). Median follow-up was 1 year.
Overall stent thrombosis rate was 6.1% (17/277) after a
median of 43 days (range 2–192 days) and affected almost
exclusively the femoropopliteal segment (12/60 in the CNS
cohort vs. 4/100 in the BNS; p = 0.001). Annualized stent
thrombosis rates (per 100 person-years) were 12.5% in case
of CNS and 1.4% in case of BNS (HR 6.3, 95% CI
2.4–17.9; p = 0.0002). Corresponding major amputations
rates were 8.7 and 2.5%, respectively (HR 4.5, 95% CI
2.7–27.9; p = 0.0006). On multivariable analysis, critical
leg ischemia and CNS placement were the only predictors
of stent thrombosis. Diabetes, critical leg ischemia,
femoropopliteal anatomy, long stents and CNS were
independent predictors of major amputations.
Conclusions Placement of long femoropopliteal covered
nitinol stents is associated with an increased incidence of
acute stent thrombosis and ensuing major amputation.
Risks are significantly lower in the aortoiliac vessels and
with use of bare nitinol stents.
Keywords Nitinol stent  Covered stent  Stent
thrombosis  Acute limb ischemia  Major amputation
Introduction
Peripheral arterial disease (PAD) has a rapidly increasing
incidence and the projected number of patients affected
globally has increased from 164 million to 202 million
between 2000 and 2010, demonstrating a nearly 25% over
10 years, while up to 3% of these patients are expected to
develop critical limb ischemia (CLI), the final stage of
PAD that is typically characterized by high risk of car-
diovascular death and lower limb amputation [1]. Treat-
ment options for symptomatic PAD include conservative
medical therapy, open surgical and more often
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percutaneous, minimally invasive, peripheral endovascular
procedures. The latter are recommended as first line
revascularization strategy in most of the cases, constantly
gaining ground compared to surgical therapies [2–4]. This
could be mainly attributed both to the growing experience
in challenging peripheral interventions and also to tech-
nological developments of safer and more efficient
endovascular devices, such as low-profile nitinol stents
[5, 6].
According to a recent mixed treatment meta-analysis of
level I evidence, use of bare metal, covered and drug-
eluting nitinol stents results in superior technical success
and patency rates compared to traditional plain balloon
angioplasty [7]. Although use of nitinol stents has been
established in everyday clinical practice for the manage-
ment of iliac or femoropopliteal arterial disease, peripheral
stent re-occlusion remains a frequent phenomenon, leading
to symptomatic recurrence and repeat interventions in the
majority of the cases [8]. Still, very little is known about
acute limb ischemia and major amputations following
development of acute peripheral stent thrombosis [9, 10].
Stent occlusion differs fundamentally from acute
thrombosis both in mechanism and clinical presentation.
While stent occlusion occurs following slow progressive
in-stent restenosis because of neointimal hyperplasia,
which allows for collateral formation, thrombosis is an
acute phenomenon occurring immediately, soon after stent
deployment (acute thrombosis), or even later (late or very
late stent thrombosis) [11]. Depending on the timing and
the available collateral network, stent re-occlusion because
of restenosis may even go undetected, whereas stent
thrombosis will usually present as limb threatening, acute
limb ischemia (ALI) at high risk of amputation [10]. We
sought to investigate the actual incidence, risk factors and
clinical implications of the phenomenon of stent throm-
bosis in the aortoiliac and infrainguinal arteries in cases of
covered nitinol stent (CNS) or bare nitinol stent (BNS)
placement.
Materials and Methods
This was a single-centre, retrospective clinical audit which
did not require Institutional review board ethics approval as
per National Health Service Research and Ethics defini-
tions (Institutional Review Board equivalent, http://www.
nres.nhs.uk/). Patient archives from a high-volume tertiary
teaching centre were audited for cases of stent thrombosis
resulting in acute limb ischemia. The study searched the
medical records of all patients treated with percutaneous
bail-out, primary, or direct, bare nitinol metal or covered
nitinol stent (stent-graft) deployment at the aortoiliac and/
or femoropopliteal arteries between January 2009 and
December 2014 to allow for adequate follow-up to date.
Hospital records were analysed in depth and patient base-
line demographics, clinical presentation at baseline, pro-
cedural and lesion characteristics, any intra-procedural and
post-procedural complications as well as follow-up visits
and repeat procedures were recorded. Completion angio-
gram of the index procedure was used to evaluate infra-
popliteal run-off vessels and a simplified 0–2 score was
used for run-off quantification, as previously reported [12].
All stent placement procedures were performed or super-
vised by nine interventional radiology or vascular surgery
consultants with a median of 5 years of experience in
peripheral arterial interventions (range 3–20 years). Stent
choice was based on operator’s preference and governed by
patient-specific clinical and anatomical criteria as part of
real-world standards of endovascular care. At the time of
implantation (2009–2014), there was little comparative
evidence to support one type of stent over the other, but
empirically, covered stents were usually chosen in cases of
chronic total occlusions and lesions with predominantly
thrombotic or heavily calcified elements in order to prevent
against distal vessel embolization. Discharge medications
and follow-up outpatient clinical appointments were also
audited. A loading dose of Clopidogrel 300 mg was rou-
tinely given if the patient had not been on regular Clopi-
dogrel prescription before, and dual antiplatelet therapy
with Aspirin 75 mg and Clopidogrel 75 mg once daily was
advised post-procedure for a duration of up to 6 months per
local Trust policy. Colour-doppler ultrasound scans, med-
ical notes relevant to the acute admission of recurrent
ischemia and digital subtraction angiograms during sub-
sequent attempts of transcatheter thrombolysis and/or other
re-interventions were examined in detail to confirm stent
thrombosis. Data analysis was performed by an interven-
tional radiology fellow and an interventional radiology
consultant (7 years of experience) in consensus.
Type of stent used during the index procedure depended
solely on the operator’s preference. CNS stents used in this
study was the GORE VIABAHN Endoprosthesis (W.
L. Gore & Associates (UK) Ltd, Livingston, UK), while a
variety of BNS stents were placed including mainly the
Zilver 635 or Zilver PTX Vascular Self-Expanding Stents
(COOK Medical Europe LTD, Limerick, IRELAND), the
GORE TIGRIS Vascular Stent (W. L. Gore & Associ-
ates (UK) Ltd, Livingston, UK) and the SUPERA
Peripheral Stent System (Abbott Vascular, IL, USA).
Baseline demographics and procedural details are outlined
in detail reported in Tables 1 and 2.
The primary outcome measure was the incidence of
definite acute stent thrombosis. Similar to the ARC clas-
sification system of coronary stent thrombosis [13], we
defined definite peripheral stent thrombosis as imaging
confirmed (Duplex ultrasonography and/or digital
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Table 1 Patient demographics Covered nitinol stents Bare nitinol stents p value
Patients (n) 91 165 –
Limbs (n) 94 183 –
Age (years) 73.9 ± 11.8 69.9 ± 11.0 0.006
Diabetes 24/91 (26.4) 56/165 (33.9) 0.21
Smoking 37/91 (40.6) 106/165 (64.2) 0.0003
Hypertension 57/91 (62.6) 72/165 (43.6) 0.0004
Hyperlipidemia 51/91 (56.0) 63/165 (38.2) 0.0006
Chronic kidney disease 33/91 (36.2) 44/165 (26.6) 0.11
Critical limb ischemia 61/94 (67.0) 75/183 (41.0) 0.0002
Lesion anatomy
Aortoiliac vessels 34/94 (36.2) 83/183 (45.3) 0.14
Aortoiliac diameter 8.5 ± 0.9 mm 8.6 ± 0.9 mm 0.59
Infrainguinal vessels 60/94 (63.8) 100/183 (54.6) 0.14
Infrainguinal diameter 5.2 ± 0.4 mm 5.1 ± 0.4 mm 0.13
Lesion mode
Arterial stenosis 16/94 (17.0) 97/183 (53.0) 0.0001
Arterial occlusion 68/94 (72.3) 86/183 (47.0) 0.0001
Acute vessel occlusion 6/94 (6.4) 5/183 (2.7) 0.19
Chronic total occlusion 62/94 (65.9) 81/183 (44.2) 0.0006
Vessel rupture 10/94 (10.6) 0/183 (0) 0.0001
Categorical data are given as counts and percentages in the parentheses
Data presented as mean ± standard deviation (SD)
Table 2 Procedural variables Covered nitinol stents Bare nitinol stents p value
Treatment mode
Subintimal angioplasty 56/94 (59.6) 80/183 (43.7) 0.006
Intraluminal angioplasty 38/94 (40.4) 103/183 (56.3) 0.006
Number of stents 1 (1–2) 1 (1–2) 0.99
Overlapping stents 29/94 (30.8) 57/183 (31.1) 1.00
Stented lesion lengtha 18.1 ± 10.1 cm 13.0 ± 10.4 cm \0.0001
Stent length (range) 2–46 cm 5–40 cm –
Aortoiliac lengtha 12.8 ± 5.0 cm 7.8 ± 4.0 cm \0.001
Aortoiliac stent diametera 8.3 ± 0.8 mm 8.2 ± 0.7 mm 0.50
Infrainguinal lengtha 21.1 ± 11.0 cm 17.5 ± 11.9 cm \0.001
Infrainguinal stent diama 5.8 ± 0.5 mm 6.1 ± 0.4 mm \0.0001
Run-off arteriesb 2 (1–2) 2 (1–3) 0.06
Antiplatelet therapy
None 3/94 (3.2) 15/183 (8.2) 0.13
Aspirin 23/94 (24.4) 61/183 (33.3) 0.13
Clopidogrel 7/94 (7.4) 21/183 (11.5) 0.29
Dual antiplatelet 54/94 (57.4) 83/183 (45.3) 0.06
Warfarin 7/94 (7.4) 3/183 (1.6) 0.03
Categorical data are given as counts and percentages in the parentheses
a Data presented as mean ± standard deviation (SD)
b Data presented as median and interquartile range (IQR) in the parentheses
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angiography) thrombotic occlusion of CNS or BNS pre-
senting with acute limb ischemia (ALI) symptoms. ALI
was defined as a sudden decrease in limb perfusion causing
a potential threat to limb viability, according to standard
clinical criteria of international guidelines [14]. Secondary
endpoints included comparison of major amputation rates
between CNS and BNS and analysis of primary patency of
the implanted stents. The latter was defined as uninter-
rupted patency of the stent demonstrated by duplex follow-
up and/or clinical and hemodynamic criteria demonstrating
maintenance of achieved improvement with no additional
procedures performed on or at the margins of the stent [15].
Major amputations were defined as any limb loss extending
above the ankle level. Cases were stratified between aor-
toiliac and femoropopliteal anatomy. We further looked for
any correlation between thrombotic and/or major amputa-
tion events with baseline anatomical, clinical and proce-
dural variables in order to identify independent predictors
of leg amputations and stent thrombosis.
Statistical Analysis
Correlation of stent thrombosis and major amputation
events with baseline anatomical and clinical variables was
first performed within a univariate framework. Next, Cox
regression multivariable analysis was performed to further
adjust for confounders and identify independent predictors
of stent failure and limb loss. Dependent variables in the
Cox model included a smoking habit, hypertension (pre-
scribed antihypertensive drug therapy), hyperlipidemia
(abnormal blood lipid levels, or prescribed drug therapy),
chronic kidney disease (serum creatinine levels[1.5 mg/dl
or dialysis), diabetes mellitus (drug therapy or insulin),
baseline symptoms (critical leg ischemia vs. intermittent
claudication), treatment site (aortoiliac vs. infrainguinal
lesions), stented lesion length (dichotomized at the median
value), baseline lesion type (chronic total occlusions vs.
stenosis), stent type (CNS vs. BNS) and prescribed anti-
platelet regiment (dual- vs. mono-therapy). Results were
expressed as Hazard ratios (HRs) with associated 95%
confidence intervals (95% CIs) as indicated for time-to-
event analyses. Kaplan–Meier survival analysis was
implemented to demonstrate the incidence of stent throm-
bosis and major amputations over time. Events were
stratified between aortoiliac and femoropopliteal anatomy.
Discrete variables are presented as counts and percentages,
while continuous variables as medians and interquartile
range in parentheses, or as means ± standard errors (SE) if
originating from normal distributions. Statistical analysis
was performed with the GraphPad Prism statistical soft-
ware package (version 5; GraphPad Software, La Jolla,
CA, USA). The Cox model was performed with the
Statsdirect statistical package (version 2.7.9; Statsdirect
Ltd, Altrincham, UK). The threshold of statistical signifi-
cance was set at p\ 0.05 for all comparisons. The lead
author was responsible for the statistical analysis.
Results
Patient Cohort
In total, 256 patients with 277 limbs were analysed with a
median of 1 (IQR 1–2) overlapping stents placed in each
segment per limb. In total, we evaluated 117 aortoiliac
stented segments (34/117; 29.0% CNS and 83/117; 71.0%
BNS) and 160 femoropopliteal stented segments (60/160;
37.5% CNS and 100/160; 62.5% BNS) (Table 2). The BNS
group included 14 limbs treated with the ZILVER-PTX
drug-eluting stent. There were no cases of drug-coated
balloon application in combination with CNS or BNS stent
placement. The majority of the patients were treated due to
chronic atherosclerotic disease (96%), while 11/277 cases
(4.0%) involved a background of acute vessel occlusions
(6/94; 6.4% with covered stents and 5/183; 2.7% with bare
stents; p = 0.19). Median follow-up period available was
1 year (389 person-years analysed).
Baseline comorbidities were more pronounced in the
CNS cohort that included significantly older (73.9 ± 11.8
vs. 69.9 ± 11.0; p = 0.006), more hypertensive (62.6 vs.
43.6%; p = 0.0004), more hyperlipidemic (56.0 vs. 38.2%;
p = 0.0006) and more CLI patients (67.0 vs. 41.0%;
p = 0.0002). On the other hand, the BNS included sig-
nificantly more smokers (64.2 vs. 40.6%; p = 0.0003). In
addition, significantly more occlusions (72.3 vs. 47.0%;
p = 0.0001), longer segments (18.1 ± 10.1 vs.
13.0 ± 10.4 cm; p\ 0.0001) and more cases of subintimal
recanalization (59.6 vs. 43.7%, p = 0.006) were included
in the CNS cohort. There were ten cases of vessel rupture
which were treated with bail-out CNS (10/94; 10.6% vs.
0/183 in the BNS group; 0%; p = 0.0001).
There were no significant differences between the two
cohorts with regard to antiplatelet therapy and run-off
arteries on the completion angiogram of the index proce-
dure (Table 2). Single antiplatelet therapy with aspirin or
Clopidorel was prescribed in 31.8% in the CNS group
compared to 44.8% in the BNS arm (p = 0.20); dual
antiplatelet was prescribed in 57.4% of the CNS cases
versus 45.3% in the BNS arm (p = 0.06).
Peripheral Stent Thrombosis
Cumulative primary patency rate was 70.2% for CNS and
72% for BNS (p = 0.72), after a median follow-up period
of 342 days (range 1–913) and 440 days (range 1–2493),
respectively. Cumulatively, stent thrombosis was
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documented in 6.1% (17/277 limbs) after a median of
43 days (range 2–192 days) and was significantly higher in
the CNS cohort (13/94; 13.8% vs. 4/183; 2.2% in the BNS
group; p = 0.0003). In the BNS group, 1 stent thrombosis
occurred in a ZILVER-PTX case. All stent thromboses
involved the femoropopliteal segment with the exception
of 1 aortoiliac CNS thrombosis (long common-external
iliac occlusion). All stent thromboses occurred in patients
with chronic peripheral occlusive disease and there was no
recurrent thrombosis noted in the subgroup of acute vessel
occlusions at baseline (17/266 vs. 0/11; p = 1.00).
Annualized event rate (per 100 person-years) of acute
stent thrombosis was 12.5% in case of covered stents and
1.4% in case of bare nitinol ones (HR 6.3, 95% CI
2.4–17.9; p = 0.0002). The majority of the thirteen CNS
thromboses were noted within the first month after the
intervention, while no acute thrombotic events were noted
after 6 months follow-up. On the contrary, all four BNS
thromboses occurred within the first month post-deploy-
ment. Time-to-event analysis of all stent thrombosis in the
aortoiliac and femoropopliteal arteries is shown in Figs. 1
and 2, respectively. On multivariable Cox regression
analysis, critical limb ischemia (HR 6.0, 95% CI
1.26–28.9; p = 0.02) and use of CNS (HR 3.4, 95% CI
1.02–11.2; p = 0.04) were found to be significant inde-
pendent predictors of stent thrombosis (Table 3).
Major Limb Amputations
Treatment mode of the thrombosed cases presenting with
ALI and detailed event rates are presented in Table 4. Most
cases were addressed with catheter-directed thrombolysis
or vein bypass surgery in case of contra-indication to
receive thrombolysis (Table 3). All major amputations
occurred in patient treated with femoropopliteal stent
placement—there were no major amputations documented
in the aortoiliac group. Within the setting of acute stent
thrombosis and ALI presentation, four major amputations
occurred within the first 2 months exclusively in the CNS
cohort (4/94; 4.2% vs. 0/183; 0.0% in the BNS; p = 0.01).
All four cases of BNS thrombosis were successfully treated
(three percutaneous catheter-directed thrombolysis and one
surgical vein bypass). Corresponding stent-thrombosis-re-
lated amputation rates were 3.9 and 0.0%, respectively.
Cumulatively, more major amputations were noted fol-
lowing CNS placement compared to BNS use. Long-term
annualized rates of lower limb loss (per 100 person-years)
were 8.7 and 2.5%, respectively (HR 4.5, 95% CI 2.7–27.9;
p = 0.0006). Time-to-event analysis of all major amputa-
tions in the aortoiliac and femoropopliteal arteries is shown
in Figs. 3 and 4, respectively. Multivariable Cox regression
analysis showed that diabetes (HR 9.9, 95% CI 2.28–43.5;
p = 0.002), critical limb ischemia (HR 10.5, 95% CI
1.80–61.3; p = 0.009), long stented segments (HR 15.1;
95% CI 2.0–114.1; p = 0.008), femoropopliteal anatomy
(HR 22.4, 95% CI 1.00–518.7; p = 0.05) and CNS
placement (HR: 7.3; 95% CI 1.41–38.0; p = 0.02) were
independent predictors of major amputations (Table 5).
Discussion
Outcomes of this real-world, retrospective analysis suggest
that stent thrombosis resulting in acute leg ischemia and
potential limb loss occurs more often in the femor-
opopliteal segment and is significantly more frequent fol-
lowing covered nitinol stent (stent-graft) compared to bare
nitinol stent. The herein cumulative stent thrombosis rate
was 6.1%, which is in line with previously published data
Fig. 1 Time-to-event analysis with the Kaplan–Meier method of
events of stent thrombosis in case of aortoiliac arteries stratified
according to the stent type used (covered and bare nitinol stent
cohorts)
Fig. 2 Time-to-event analysis with the Kaplan–Meier method of
events of stent thrombosis in case of femoropopliteal arteries stratified
according to the stent type used (covered and bare nitinol stent
cohorts)
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Table 3 Univariate and







Smoking 1.34 (0.52–3.47) 1.08 (0.37–3.09) 0.89
Hypertension 1.05 (0.37–2.99) 0.87 (0.27–2.83) 0.82
Hyperlipidemia 1.53 (0.56–4.15) 1.11 (0.33–3.67) 0.87
Chronic kidney disease 0.95 (0.34–2.71) 0.75 (0.25–2.23) 0.61
Diabetes mellitus 2.28 (0.88–5.92) 1.55 (0.51–4.66) 0.44
Critical limb ischemia 9.56 (2.18–41.9) 6.03 (1.26–28.9) 0.02
Femoropopliteal anatomy 9.64 (1.28–72.7) 5.54 (0.66–46.6) 0.11
Stented lesion length 4.79 (1.38–16.7) 1.86 (0.43–8.13) 0.41
Chronic total occlusions 3.73 (1.07–13.0) 1.95 (0.45–8.39) 0.37
Stent grafts 6.27 (2.04–19.2) 3.38 (1.02–11.2) 0.04
Dual antiplatelet agents 0.91 (0.34–2.46) 1.00 (0.33–3.06) 0.99
Categorical data are given as counts and percentages in the parentheses
a Data presented as median and range in the parentheses
Table 4 Primary and
secondary outcome measures
Covered nitinol stents Bare nitinol stents p value
Follow-up (days)a 342 (1–913) 440 (1–2493) –
Follow-up (person-years) 104.0 284.8 –
Stent primary patency 66/94 (70.2) 132/183 (72.1) 0.74
Stent thrombosis 13/94 (13.8) 4/183 (2.2) 0.0003
Event rate (per 100 person-years) 12.5% 1.4% –
Treatment mode
Catheter thrombolysis 8/13 (61.5) 3/4 (75.0) 1.00
Successful thrombolysis 5/13 (38.4) 3/3 (100) 0.04
Surgical bypass 3/13 (23.1) 1/4 (25.0) 1.00
Major leg amputations 4/94 (4.2) 0/183 (0.0) 0.01
Event rate (per 100 person-years) 3.9% 0.0% –
Overall leg amputations 9/94 (9.6) 7/183 (3.8) 0.06
Event rate (per 100 person-years) 8.7% 2.5% –
Fig. 3 Time-to-event analysis with the Kaplan–Meier method of
major lower limb amputations in case of aortoiliac arteries stratified
according to the stent type used (covered and bare nitinol stent
cohorts)
Fig. 4 Time-to-event analysis with the Kaplan–Meier method of
major lower limb amputations in case of femoropopliteal arteries
stratified according to the stent type used (covered and bare nitinol
stent cohorts)
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indicating that peripheral stent thrombosis is not a very rare
phenomenon. In a similar setting, Vartanian et al. recently
reported a nearly identical overall rate of 6.7% femor-
opopliteal stent thrombosis presenting with acute limb
ischemia [10]. The authors also stratified their results
according to type of stent, i.e., bare versus covered ones.
According to the published subgroup analysis, there was no
BNS thrombosis compared to nine thrombotic events
resulting in ALI following CNS implantation (CNS 12 vs.
0% for bare stents; p\ 0.05) [10]. These results are very
similar to the herein presented findings of cumulative
13.8% covered stent thrombosis versus 2.2% in case of
bare nitinol ones.
However, it must be stressed that the present results
should be interpreted with caution as significantly longer,
more complex lesions and significantly more CLI patients
were included in the CNS arm. Still, multivariable analysis
adjusted for confounders and actually identified stented
lesion length as an independent predictor of major leg
amputations, while CLI was correlated with both increased
risk of stent thrombosis and major leg amputations. Nota-
bly, placement of covered stents was associated with an
increased risk of both acute stent thrombosis (adjusted
hazard ratio of 3.4 times) and future major amputations
(adjusted hazard ratio of 7.3 times). The majority of our
cases were prescribed on dual antiplatelet therapy (DAPT).
However, we could not associate DAPT with a decreased
risk of neither stent thrombosis nor major amputations, as
previously reported in the literature [16]. Arguably, the
Cox model may have limited power to detect any weak
covariate relationships because of the relatively small
number of event counts (17 stent thromboses and 16 major
amputations, in total). In addition, we had no information
available about the actual duration and patient compliance
on DAPT. Dual antiplatelets and in particular patient
responsiveness to Clopidogrel have been shown to
significantly affect stent patency and long-term clinical
outcomes and limb salvage [16–18].
Other studies investigating the use of covered stents in
the femoropopliteal arteries have reported even higher rates
of stent thrombosis. In particular, Golchehr et al. reported a
23% stent thrombosis rate within a 10-year period in a
retrospective analysis of patients treated with ePTFE stent
grafts in the superficial femoral artery (SFA) [19]. Of
interest, 4-year results from the randomized comparison of
percutaneous ePTFE stent-graft deployment versus pros-
thetic femoral-popliteal bypass demonstrated a high 36%
rate of covered nitinol stent thrombosis with a mean time to
thrombosis of 11.3 ± 6 months (range 1 h to 24 months)
[20]. In the present study, CNS thrombosis occurred mainly
within the first 6 months with a median time to thrombosis
of around 1 month and a half. Stent oversizing[20% has
been incriminated for covered stent failure and is a key
technical consideration with VIABAHN stent use [21–23].
In the present study, the distribution of CNS diameters
suggested more conservative sizing in case of covered stent
placement in our cohort.
Another important finding of the present study is the
incidence of bare nitinol stent thrombosis, which was found
to be 1.4 events per 100 person-years and affected again
exclusively the femoropopliteal artery. Of interest, the
recently published ZEPHYR registry of the ZILVER-PTX
paclitaxel-eluting nitinol stents in the femoropopliteal
segment reported a 2% definite stent thrombosis rate at
1 year [24]. In the present series, we had one case of acute
ZILVER-PTX thrombosis as well. Our findings are also
congruent with the recent report by the XL-Pad registry on
the incidence of femoropopliteal stent thrombosis.
According to the XL-PAD findings, the rate of stent
thrombosis was similar between drug-eluting and bare-
metal stents (4.4 vs. 3.4%; p = 0.55), but significantly
higher in the case of self-expanding covered stents as
Table 5 Univariate and







Smoking 1.27 (0.47–3.42) 2.01 (0.59–6.88) 0.26
Hypertension 0.77 (0.28-2.14) 0.57 (0.16-2.00) 0.38
Hyperlipidemia 0.62 (0.22–1.69) 0.16 (0.04–0.76) 0.02
Chronic kidney disease 1.09 (0.37–3.17) 0.78 (0.24–2.50) 0.68
Diabetes mellitus 4.88 (1.69–14.1) 9.95 (2.28–43.5) 0.002
Critical limb ischemia 8.54 (1.93–37.8) 10.5 (1.80–61.3) 0.009
Femoropopliteal anatomy 24.9 (1.46–425.7) 22.4 (1.00–518.7) 0.05
Stented lesion length 8.50 (1.93–37.4) 15.1 (2.0–114.1) 0.008
Chronic total occlusions 1.49 (0.54–4.10) 0.65 (0.15–2.79) 0.57
Stent grafts 7.29 (1.95–27.2) 7.33 (1.41–38.0) 0.02
Dual antiplatelet agents 1.05 (0.37–2.93) 1.57 (0.51–4.83) 0.44
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compared with bare-metal stents (10.6 vs. 3.4%; p = 0.02)
[28].
To our knowledge, this is the first series reporting four
individual cases of peripheral bare nitinol stent thrombosis
resulting in limb-threatening acute ischemia. Notably, all
four cases were successfully treated with either percuta-
neous catheter-directed thrombolysis or bypass surgery
avoiding major amputation. On the contrary, nearly a third
of the herein reported CNS thromboses (4 out of 13)
resulted in major amputation compared to none from the
bare nitinol group. This could be attributed to the fact that
CNS thrombosis would be similar to surgical bypass
thrombosis from a pathophysiological point of view. In the
absence of adequate collateral arterial network to support
foot perfusion, especially in cases of long infrainguinal
covered stents, thrombosis may manifest as acute limb-
threatening ischemia and urgent thrombolysis or bypass
surgery may be the only effective means of treatment.
Hence, ischemia following CNS thrombosis may develop
clinically in a more abrupt and pronounced way putting the
foot at risk of amputation, and its management may be
technically more demanding, because of the PTFE
excluding collateral networks especially in cases with poor
foot run-off. Treatment of peripheral stent-graft thrombosis
with transcatheter thrombolysis and/or mechanical
thrombectomy has been reported in the literature with
success rates ranging from 49 to 95%, while in cases of
failed lysis/thrombectomy, surgical bypass has been a valid
alternative in order to prevent imminent amputation but
unfortunately not always successfully [19, 20].
We have also identified critical limb ischemia as an
independent predictor of stent thrombosis and not surpris-
ingly limb loss as well. A possible explanation could be
that the complexity of arterial disease in terms of lesion
length, severe calcifications and increased platelet reac-
tivity noted in CLI patients may have contributed to the
increased risk of stent thrombosis [17]. Moreover, pro-
gressive atherosclerotic disease affecting the distal and/or
proximal stent landing zone could be another factor con-
tributing to stent thrombosis especially in cases of covered
stents, while thrombogenic intramural hematomas follow-
ing stenting of long arterial subintimal dissection could be
another possible mechanism for early bare-metal stent
thrombosis. Diabetes (HR 9.9; p = 0.002), critical leg
ischemia (HR 10.5; p = 0.009) and long lesions (HR 15.1;
p = 0.008) were also found to be highly significant pre-
dictors of major limb loss as previously reported in the
literature [24–27].
Limitations of this study include its single-centre, ret-
rospective design that would account for the heterogeneity
noted in the baseline demographic and procedural variables
between the two stent cohorts. There is also an inherent
operator selection bias because of more covered stent use
in long femoropopliteal occlusions treated with a subinti-
mal technique. Moreover, although hospital files were
thoroughly searched, some cases of stent thrombosis and/or
ALI might have been overlooked or may have developed in
a more clinically subtle fashion and have been considered
as chronic stent re-occlusions. However, similar to the
ARC classification system of coronary stent thrombosis
[13], we defined definite peripheral stent thrombosis as
imaging confirmed stent thrombosis presenting with acute
limb ischemia symptoms. The present study may also be
underpowered in the aortoiliac vessels, considering the
very low frequency of the phenomenon in that particular
anatomy. Nonetheless, until today this is the largest series
reporting the incidence and key risk factors of peripheral
stent thrombosis adding valuable data about the potential
clinical implications of early or late stent failure in the
femoropopliteal segment.
In conclusion, peripheral artery stent thrombosis is an
infrequent but truly serious phenomenon that may present
with acute limb ischemia at risk of limb loss. Placement of
long femoropopliteal covered nitinol stents is associated
with an increased incidence of acute stent thrombosis and
ensuing major amputation in particular. Risks are signifi-
cantly lower in the aortoiliac vessels and with the use of
bare nitinol stents. More studies are warranted considering
the low frequency of the phenomenon.
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